|
[1]
|
International Agency for Research on Cancer (2014) World cancer report 2014. In: Stewart, B.W. and Wild, C.P., Eds., WHO Press, Lyon, 16-53.
|
|
[2]
|
Kalir, T., Firpo-Betancourt, A. and Nezhat, F. (2013) Update on ovarian cancer patho-genesis: History, controversies, emerging issues and future impact. Expert Review of Obstetrics & Gynecology, 8, 539-547.
http://dx.doi.org/10.1586/17474108.2013.847638 [Google Scholar] [CrossRef]
|
|
[3]
|
Auersperg, N., Wong, A.S.T., Choi, K.C., et al. (2001) Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocrine Reviews, 22, 255-288.
|
|
[4]
|
Marchetti, C., Pisano, C., Facchini, G., Bruni, G.S., Magazzino, F.P., Losito, S. and Pignata, S. (2010) Fist-line treatment of ovarian cancer: Current research and perspectives. Expert Review, 10, 47-60.
http://dx.doi.org/10.1586/era.09.167 [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Hajitou, A., Pasqualini, R. and Arap, W. (2006) Vascular targeting: Recent advances and therapeutic perspectives. Trends in Cardiovascular Medicine, 16, 80-88. http://dx.doi.org/10.1016/j.tcm.2006.01.003 [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Kigawa, J. (2013) New Strategy for Overcoming Resistance to Chemotherapy of Ovarian Cancer. Yonago Acta Medica, 56, 43-50.
|
|
[7]
|
Janczar, S., Graham, J.S., Paige, A.J.W. and Gabra, H. (2009) Targeting locoreginal peritoneal dissemination in ovarian cancer. Expert Review of Obstetrics & Gy-necology, 4, 133-147. http://dx.doi.org/10.1586/17474108.4.2.133 [Google Scholar] [CrossRef]
|
|
[8]
|
Lafky, J.M., Wilken, J.A., Baron, A.I., et al. (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1785, 232-265.
http://dx.doi.org/10.1016/j.bbcan.2008.01.001 [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Wilken, J.A., Badri, T., Cross, S., et al. (2012) EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry, 4, 447-469. http://dx.doi.org/10.4155/fmc.12.11 [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Xia, B., Yang, S., Liu, T., et al. (2015) miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Molecular Cancer, 14, 57. http://dx.doi.org/10.1186/s12943-015-0322-4 [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zhang, H.Y., Zhang, X.L., Ji, S.F., et al. (2014) Sohlh2 inhibits ovarian cancer cell proliferation by up regulation of p21 and down regulation of cyclin D1. Carcinogenesis, 35, 1863-1871. http://dx.doi.org/10.1093/carcin/bgu113 [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Yang, Z.Y., Zhou, X.S., Liu, Y., et al. (2014) Activation of integrin beta 1 mediates the increased malignant potential of ovarian cancer cells exerted by inflammatory cytokines. Anti-Cancer Agents in Medicinal Chemistry, 14, 955-962.
http://dx.doi.org/10.2174/1871520614666140613123108 [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Adams, G.P. and Weiner, L.M. (2005) Monoclonal antibody therapy of cancer. Nature Biotechnology, 23, 1147-1157. http://dx.doi.org/10.1038/nbt1137 [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Brown, K.C. (2010) Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Current Pharmaceutical Design, 16, 1040-1054. http://dx.doi.org/10.2174/138161210790963788 [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Akita, N., Maruta, F., Seymour, L.W., Kerr, D.J., Parker, A.L., et al. (2006) Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Science, 97, 1075-1081.
http://dx.doi.org/10.1111/j.1349-7006.2006.00291.x [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Chen, B., Cao, S., Zhang, Y., et al. (2009) A novel pep-tide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biology, 10, 63.
http://dx.doi.org/10.1186/1471-2121-10-63 [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Du, B., Han, H., Wang, Z., et al. (2010) Targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. Molecular Cancer Research, 8, 135-144. http://dx.doi.org/10.1158/1541-7786.MCR-09-0339 [Google Scholar] [CrossRef]
|
|
[18]
|
Laakkonen, P., Porkka, K., Hoffman, J.A., et al. (2002) A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nature Medicine, 8, 751-755. http://dx.doi.org/10.1038/nm720 [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) Cancer treatment by tar-geted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380. http://dx.doi.org/10.1126/science.279.5349.377 [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Hajitou, A., Trepel, M., Lilley, C.E., et al. (2006) A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell, 125, 385-398. http://dx.doi.org/10.1016/j.cell.2006.02.042 [Google Scholar] [CrossRef] [PubMed]
|